Checkpoint Therapeutics, Inc. Forecast, price target & analysts
Checkpoint Therapeutics, Inc. Target price 2025 - Analyst rating & recommendation
Checkpoint Therapeutics, Inc. Classifications & Recommendation:
Checkpoint Therapeutics, Inc. Price Target
| Target Price | $4.33 |
| Price | $4.11 |
| Potential |
5.43%
register free of charge
|
| Number of Estimates | 3 |
|
3 Analysts have issued a price target Checkpoint Therapeutics, Inc. 2026 .
The average Checkpoint Therapeutics, Inc. target price is $4.33.
This is
5.43%
register free of charge
$4.80
16.79%
register free of charge
$4.10
0.24%
register free of charge
|
|
| A rating was issued by 3 analysts: 1 Analysts recommend Checkpoint Therapeutics, Inc. to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Checkpoint Therapeutics, Inc. stock has an average upside potential 2026 of
5.43%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 0.04 | 41.11 |
| 60.00% | 102,685.00% | |
| Net Margin | -192,907.00% | -23.13% |
| 28.16% | 99.99% |
2 Analysts have issued a sales forecast Checkpoint Therapeutics, Inc. 2025 . The average Checkpoint Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
2 Checkpoint Therapeutics, Inc. Analysts have issued a net profit forecast 2025. The average Checkpoint Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.42 | -0.18 |
| 48.74% | 87.32% | |
| P/E | negative | |
| EV/Sales | 8.54 |
2 Analysts have issued a Checkpoint Therapeutics, Inc. forecast for earnings per share. The average Checkpoint Therapeutics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Checkpoint Therapeutics, Inc....
Current Checkpoint Therapeutics, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| D. Boral Capital |
Locked
➜
Locked
|
Locked | Mar 31 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 11 2025 |
| D. Boral Capital |
Locked
➜
Locked
|
Locked | Mar 10 2025 |
| Lake Street |
Locked
➜
Locked
|
Locked | Mar 10 2025 |
| D. Boral Capital |
Locked
➜
Locked
|
Locked | Jan 13 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Dec 16 2024 |
| Lake Street |
Locked
➜
Locked
|
Locked | Dec 16 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
D. Boral Capital:
Locked
➜
Locked
|
Mar 31 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 11 2025 |
|
Locked
D. Boral Capital:
Locked
➜
Locked
|
Mar 10 2025 |
|
Locked
Lake Street:
Locked
➜
Locked
|
Mar 10 2025 |
|
Locked
D. Boral Capital:
Locked
➜
Locked
|
Jan 13 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Dec 16 2024 |
|
Locked
Lake Street:
Locked
➜
Locked
|
Dec 16 2024 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
